Edwards cuts Q3 revenue outlook as heart valve sales hit by EU austerity measures
This article was originally published in Clinica
Edwards Lifesciences' has lowered its revenue estimate for the third fiscal quarter, as sales of its transcatheter heart valves (THVs) were affected by weakness in the European market. The company is now expecting total sales of $448 million in Q3, compared with previous guidance of $465-485 million. Q3 sales of its THVs, including Sapien, were "below expectations" in Q3 at $124 million globally, and $55 million in the US.